Misonix has announced that it has entered into an agreement with Aesculap to acquire back the rights to the remaining accounts, as of March 1, 2015, exclusively being managed by Aesculap for the Misonix BoneScalpel ultrasonic bone cutting system.
Since December 2012, under a non-exclusive distribution agreement, Aesculap retained the right to sell BoneScalpel disposables in the USA to certain, limited hospital accounts which are covered by binding supply agreements for varying periods of time, but not to exceed three years. The BoneScalpel is a novel ultrasonic surgical system used for safe, tissue-selective bone dissection that encourages en bloc bone removal and refined osteotomies while sparing elastic soft tissue structures.
“We are thankful to Aesculap and their professional management of, and efforts in, servicing these strategically important accounts,” said Michael A McManus Jr, president and chief executive officer of Misonix. “This new agreement moves Misonix an important additional step further along the path of complete control of BoneScalpel distribution in the USA through the company’s own growing network of sales representatives.”